Previous 10 | Next 10 |
Orphazyme (ORPH) ADRs have added more than 37% in early trading Thursday on above average volume as investors look past the recent operational issues of the Danish biotech that led to a three-day selloff. About 2 million ADRs have changed hands so far in the pre-market compared to t...
Orphazyme (ORPH -39.8%) stock plummeted after the company said it intends to delist its American Depositary Shares ((ADSs)) from Nasdaq and reduce its global workforce by ~50%. The company said that after receipt of a negative Trend Vote — for its marketing applicat...
Gainers: Clearside Biomedical CLSD +38%. Cellectis (NASDAQ:CLLS) +13%. NeuroPace (NASDAQ:NPCE) +12%. 4D pharma LBPS +11%. LifeStance Health (NASDAQ:LFST) +8%. Losers: Orphazyme ORPH -37%. Aesthetic Medical International (NASDAQ:AIH) -19%. Suns...
Orphazyme (NASDAQ:ORPH) -39% on commencement of in-court restructuring. Tilly's (NYSE:TLYS) -25% on Q4 earnings release. AgriFORCE Growing Systems (NASDAQ:AGRI) -18%. DocuSign (NASDAQ:DOCU) -16% on Q4 earnings release. Sunworks (NASDAQ:SUNW) -15% o...
Denmark-based Orphazyme (NASDAQ:ORPH) appointed CFO Anders Vadsholt as CEO, effective March 1, a month before the previously announced date. Vadsholt will be replacing outgoing CEO Christophe Bourdon who is taking up the role of CEO of LEO Pharma, effective April 1 ORPH -7.14% ...
Gainers: Indonesia Energy Corporation (NYSE:INDO) +65%. Camber Energy (NYSE:CEI) +40%. South Jersey Industries (NYSE:SJI) +40%. Post Holdings (NYSE:POST) +34%. Lantheus Holdings (NASDAQ:LNTH) +33%. Imperial Petroleum (NASDAQ:IMPP) +30%. Cyren (NASDAQ:CYRN) +28%. TransMedics Group (NASDAQ:TMDX...
Gainers: Lantheus (NASDAQ:LNTH) +34%. Evolent Health (NYSE:EVH) +18%. Clover Health (NASDAQ:CLOV) +10%. Liquidia (NASDAQ:LQDA) +10%. iRhythm Technologies (NASDAQ:IRTC) +8%. Losers: Orphazyme (NASDAQ:ORPH) -36%. Rhythm Pharmaceuticals (NASDAQ:RYTM) -24%. Tabu...
Skillz (NYSE:SKLZ) -37% on Q4 earnings release. Rent-A-Center (NASDAQ:RCII) -35% on Q4 earnings release. Yandex (NASDAQ:YNDX) -34%. Ozon Holdings (NASDAQ:OZON) -32%. Mechel (NYSE:MTL) -31%. Orphazyme (NASDAQ:ORPH) -31% after suffers regulatory setback for EU...
The ADRs of Danish biotech Orphazyme (NASDAQ:ORPH) is trading ~3% lower in the post-market on Wednesday after the company indicated that it is unlikely to receive the EU nod for its current marketing application for arimoclomol in Niemann-Pick disease type C (NPC). Regarding its rev...
Orphazyme (ORPH +16.7%) ADRs are trading sharply higher on Friday after the Danish biotech announced its plans to resubmit the U.S. marketing application for arimoclomol in H2 2022 targeting patients with Niemann-Pick disease type C (NPC). Last June, the FDA declined to approve the treatment ...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...